TACE-HAIC plus TKIs with/without PD-1 inhibitors for unresectable hepatocellular carcinoma: a propensity score matching study
Frontiers in Oncology · 14.08.2026 · 16
DOI: 10.3389/fonc.2026.1874177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 14.08.2026. Verfasst von Xiadi Weng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Fujian Province, Science and Technology Planning Project of Fuzhou.
Abstract (Originalsprache)
Background and aims Patients with unresectable hepatocellular carcinoma (uHCC) have a poor prognosis, and effective systemic treatment options remain limited. We aimed to evaluate the safety and efficacy of adding programmed death-1 (PD-1) inhibitors to transarterial chemoembolization combined with hepatic arterial infusion chemotherapy (TACE-HAIC)+lenvatinib.
Methods
We retrospectively analyzed data from patients with uHCC who received TACE-HAIC+lenvatinib, without or with PD-1 inhibitors (n = 124). Patients were stratified into a triple-therapy group (TACE-HAIC+lenvatinib; n = 71) and a quadruple-therapy group (TACE-HAIC+lenvatinib+PD-1 inhibitors; n = 53), based on whether PD-1 inhibitors were included in the first-line regimen. Overall survival (OS), progression-free survival (PFS), and adverse event rate were compared between the groups. Propensity score matching was performed to reduce confounding bias.
Results
After propensity score matching (PSM), 43 matched pairs were identified. The median OS was 11.0 months [95% confidence interval (CI), 10.0–16.0] in the triple-therapy group and 25.0 months (95% CI: 12.0–not reached) in the quadruple-therapy group. The median PFS was 8.6 months (95% CI: 6.37–11.77) and 12.1 months (95% CI: 8.7–not reached), respectively. Both OS and PFS were significantly improved in the quadruple-therapy group (P < 0.05).
Conclusions
The addition of PD-1 inhibitors to TACE-HAIC plus lenvatinib significantly improved both OS and PFS without a statistically significant increase in adverse events. However, careful monitoring and prompt management of immune-related adverse events remain warranted during treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
- Department of Interventional Radiology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
- Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Förderung
- Natural Science Foundation of Fujian Province
- Science and Technology Planning Project of Fuzhou
Zitieren
APA
Weng, X., Zhou, Y., Fang, G., & Zeng, Y. (2026). TACE-HAIC plus TKIs with/without PD-1 inhibitors for unresectable hepatocellular carcinoma: a propensity score matching study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1874177
Vancouver
Weng X, Zhou Y, Fang G, Zeng Y. TACE-HAIC plus TKIs with/without PD-1 inhibitors for unresectable hepatocellular carcinoma: a propensity score matching study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1874177
BibTeX
@article{Weng2026,
author = {Weng, Xiadi and Zhou, Yang and Fang, Guoxu and Zeng, Yongyi},
title = {TACE-HAIC plus TKIs with/without PD-1 inhibitors for unresectable hepatocellular carcinoma: a propensity score matching study},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1874177}
}
EUVIMED